Definition of biogeneric in English:

biogeneric

adjective & noun ˌbʌɪə(ʊ)dʒəˈnɛrɪk

the advent of biogenerics could cause biotech companies to withhold more information about their products
another term for biosimilar
biogeneric versions of off-patent medicines
Example sentencesExamples
- "You get one crack at it," said Robert Coughlin, president of the Massachusetts Biotechnology Council, speaking of the task of drawing up a licensing system for "biogenerics."
- The FDA has been trying to get its regulatory head around the issue of biogeneric equivalency, but it isn't easy.
- CCPM coalition members urged Congress to fix or drop the current biogenerics provision.
- "I feel that a value of $1 billion is reasonable for a proven technological platform in the generics sector, especially in biogenerics, which currently very much interests the major firms."
- If competing firms are permitted to manufacture them, biogeneric versions of the off-patent medicines could command $5 billion next year.
- Rules in the U.S. are still unclear, making it difficult for companies to win approval to market biogenerics there.
- Some biotech drug manufacturers are lobbying state legislators to restrict access to biosimilar (or biogeneric) versions of expensive brand medications, the Pharmaceutical Care Management Association (PCMA) said today.
- Large growth is expected to come on the back of increased partnering activity, transition to product-driven models, growth in the biogenerics market and government initiatives to encourage investment and expansion.
- At the same time that Amgen is getting ready to launch its own biosimilars, Amgen and other biotechs are campaigning state governments to make it harder to substitute a biogeneric for a brand.

Origin

1990s: from bio- + generic.

Definition of biogeneric in US English:

biogeneric

noun & adjectiveˌbīōjəˈnerikˌbaɪoʊdʒəˈnɛrɪk

the advent of biogenerics could cause biotech companies to withhold more information about their products
another term for biosimilar
biogeneric versions of off-patent medicines
Example sentencesExamples
- If competing firms are permitted to manufacture them, biogeneric versions of the off-patent medicines could command $5 billion next year.
- Rules in the U.S. are still unclear, making it difficult for companies to win approval to market biogenerics there.
- "You get one crack at it," said Robert Coughlin, president of the Massachusetts Biotechnology Council, speaking of the task of drawing up a licensing system for "biogenerics."
- At the same time that Amgen is getting ready to launch its own biosimilars, Amgen and other biotechs are campaigning state governments to make it harder to substitute a biogeneric for a brand.
- Large growth is expected to come on the back of increased partnering activity, transition to product-driven models, growth in the biogenerics market and government initiatives to encourage investment and expansion.
- "I feel that a value of $1 billion is reasonable for a proven technological platform in the generics sector, especially in biogenerics, which currently very much interests the major firms."
- CCPM coalition members urged Congress to fix or drop the current biogenerics provision.
- Some biotech drug manufacturers are lobbying state legislators to restrict access to biosimilar (or biogeneric) versions of expensive brand medications, the Pharmaceutical Care Management Association (PCMA) said today.
- The FDA has been trying to get its regulatory head around the issue of biogeneric equivalency, but it isn't easy.

Origin

1990s: from bio- + generic.

词汇	biogeneric
释义	Definition of biogeneric in English: biogeneric adjective & noun ˌbʌɪə(ʊ)dʒəˈnɛrɪk the advent of biogenerics could cause biotech companies to withhold more information about their products another term for biosimilar biogeneric versions of off-patent medicines Example sentencesExamples "You get one crack at it," said Robert Coughlin, president of the Massachusetts Biotechnology Council, speaking of the task of drawing up a licensing system for "biogenerics." The FDA has been trying to get its regulatory head around the issue of biogeneric equivalency, but it isn't easy. CCPM coalition members urged Congress to fix or drop the current biogenerics provision. "I feel that a value of $1 billion is reasonable for a proven technological platform in the generics sector, especially in biogenerics, which currently very much interests the major firms." If competing firms are permitted to manufacture them, biogeneric versions of the off-patent medicines could command $5 billion next year. Rules in the U.S. are still unclear, making it difficult for companies to win approval to market biogenerics there. Some biotech drug manufacturers are lobbying state legislators to restrict access to biosimilar (or biogeneric) versions of expensive brand medications, the Pharmaceutical Care Management Association (PCMA) said today. Large growth is expected to come on the back of increased partnering activity, transition to product-driven models, growth in the biogenerics market and government initiatives to encourage investment and expansion. At the same time that Amgen is getting ready to launch its own biosimilars, Amgen and other biotechs are campaigning state governments to make it harder to substitute a biogeneric for a brand. Origin 1990s: from bio- + generic. Definition of biogeneric in US English: biogeneric noun & adjectiveˌbīōjəˈnerikˌbaɪoʊdʒəˈnɛrɪk the advent of biogenerics could cause biotech companies to withhold more information about their products another term for biosimilar biogeneric versions of off-patent medicines Example sentencesExamples If competing firms are permitted to manufacture them, biogeneric versions of the off-patent medicines could command $5 billion next year. Rules in the U.S. are still unclear, making it difficult for companies to win approval to market biogenerics there. "You get one crack at it," said Robert Coughlin, president of the Massachusetts Biotechnology Council, speaking of the task of drawing up a licensing system for "biogenerics." At the same time that Amgen is getting ready to launch its own biosimilars, Amgen and other biotechs are campaigning state governments to make it harder to substitute a biogeneric for a brand. Large growth is expected to come on the back of increased partnering activity, transition to product-driven models, growth in the biogenerics market and government initiatives to encourage investment and expansion. "I feel that a value of $1 billion is reasonable for a proven technological platform in the generics sector, especially in biogenerics, which currently very much interests the major firms." CCPM coalition members urged Congress to fix or drop the current biogenerics provision. Some biotech drug manufacturers are lobbying state legislators to restrict access to biosimilar (or biogeneric) versions of expensive brand medications, the Pharmaceutical Care Management Association (PCMA) said today. The FDA has been trying to get its regulatory head around the issue of biogeneric equivalency, but it isn't easy. Origin 1990s: from bio- + generic.
随便看	pass the buck pass the buck pass the hat pass the hat pass the hat pass the hat pass the hat round pass the hat round pass the hat round (or pass the hat) pass the parcel pass the parcel pass the time pass the time of day pass the time of day pass the time of day pass-through inviolableness inviolably inviolably inviolacy inviolacy inviolate inviolated inviolately inviolately inviolateness